| DNAJC6 Gene | |
|---|---|
| Gene Symbol | DNAJC6 |
| Full Name | DNAJ Heat Shock Protein Family (Hsp40) Member C6 |
| Chromosomal Location | 1p31.3 |
| NCBI Gene ID | [9837](https://www.ncbi.nlm.nih.gov/gene/9837) |
| OMIM | [618375](https://www.omim.org/entry/618375) |
| Ensembl ID | ENSG00000138231 |
| UniProt ID | [O75037](https://www.uniprot.org/uniprot/O75037) |
| Associated Diseases | Early-Onset Parkinson's Disease, Atypical Parkinsonism, Juvenile Parkinsonism |
DNAJC6 (DNAJ Heat Shock Protein Family (Hsp40) Member C6), also known as Auxilin-1, is a critical neuronal gene located on chromosome 1p31.3 that encodes a co-chaperone protein essential for synaptic vesicle recycling and protein quality control. The gene encodes a 935-amino acid protein with a molecular weight of approximately 104 kDa, containing an N-terminal co-chaperone J domain, a central client-binding region, and a C-terminal clathrin-binding domain[1][2].
DNAJC6 is expressed predominantly in neuronal tissues, with highest expression in the substantia nigra pars compacta, striatum, hippocampus, and cerebral cortex[^3]. The protein localizes to presynaptic terminals where it performs essential functions in clathrin-mediated endocytosis, the primary mechanism by which synaptic vesicles are recycled after neurotransmitter release.
Mutations in DNAJC6 cause autosomal recessive early-onset Parkinson's disease (PD), typically presenting before age 20 with an excellent response to levodopa therapy. This identification of DNAJC6 as a PD gene has provided important insights into the role of synaptic vesicle endocytosis in neurodegeneration[4][5].
The DNAJC6 gene spans approximately 35 kb and consists of 15 exons. The encoded protein, auxilin-1, contains several functional domains:
J Domain (aa 1-70): The N-terminal J domain is conserved across all DNAJ/Hsp40 family members and functions to stimulate the ATPase activity of Hsp70 chaperones. This domain contains the highly conserved HPD motif (His-Pro-Asp) essential for Hsp70 interaction[^6].
Client-Binding Region (aa 200-500): This region contains multiple glycine-phenylalanine (GF)-rich sequences that facilitate binding to a broad range of client proteins, including components of the clathrin coat machinery.
Clathrin-Binding Domain (aa 600-700): The C-terminal region contains multiple clathrin box motifs (LLDLF) that enable direct binding to the clathrin triskelion, essential for the protein's role in clathrin uncoating[^7].
Phosphorylation Sites: Multiple serine/threonine phosphorylation sites regulate the protein's activity throughout the cell cycle and during synaptic activity.
DNAJC6 shows tissue-specific expression with highest levels in neuronal tissues:
| Tissue Type | Expression Level | Localization |
|---|---|---|
| Substantia nigra | Very High | Dopaminergic neurons |
| Striatum | High | Medium spiny neurons |
| Hippocampus | High | CA1-CA3 pyramidal cells |
| Cerebral cortex | High | Layer 5 pyramidal neurons |
| Testis | Moderate | Spermatogenic cells |
| Kidney | Low | Tubular cells |
Within neurons, DNAJC6 localizes to:
DNAJC6/Auxilin-1 plays a pivotal role in synaptic vesicle recycling through its involvement in clathrin-mediated endocytosis (CME). The process of synaptic vesicle recycling is essential for maintaining neurotransmitter release during sustained neuronal activity, as each vesicle fusion event requires the retrieval and reuse of synaptic vesicle components[^8].
The mechanism of DNAJC6 function involves:
Recruitment to Clathrin-Coated Vesicles: Following vesicle fusion and neurotransmitter release, DNAJC6 is recruited to the newly formed clathrin-coated vesicle (CCV) through direct binding to clathrin triskelions via its C-terminal clathrin-binding domain[^9].
Hsp70 Recruitment: DNAJC6's J domain recruits Hsp70 (primarily HSPA8/HSPA1A) to the clathrin coat. The J domain stimulates Hsp70 ATP hydrolysis, converting Hsp70 to its high-affinity state for clathrin binding.
Clathrin Uncoating: The recruited Hsp70 proteins, bound to DNAJC6, work in concert to dissociate clathrin triskelions from the vesicle membrane. This ATP-dependent uncoating process is critical for the formation of fusion-competent synaptic vesicles[^10].
Vesicle Reacidification: Following uncoating, the vesicle must be reacidified by V-ATPase to resume its role as a functional synaptic vesicle. DNAJC6 deficiency impairs this process, leading to vesicle pool depletion[^11].
Beyond its role in endocytosis, DNAJC6 functions as a co-chaperone in protein quality control systems:
DNAJC6 interacts with multiple protein partners essential for its function:
| Partner | Interaction Type | Function |
|---|---|---|
| HSPA8 (Hsc70) | Co-chaperone | Clathrin uncoating |
| HSPA1A (Hsp70-1) | Co-chaperone | Stress response |
| DNAJA1 (Hsp40) | Co-chaperone | Chaperone complex formation |
| CLTC (Clathrin heavy chain) | Direct binding | Coat assembly/uncoating |
| AP2 complex | Indirect | Endocytic adaptor |
| SYNJ1 (Synaptojanin 1) | Functional | Phosphoinositide metabolism |
| DNM1L (Dynamin 1) | Functional | Vesicle scission |
DNAJC6 mutations were first identified as a cause of autosomal recessive early-onset Parkinson's disease in 2014[^4]. The disease typically presents in adolescence or early adulthood (before age 20) with the following characteristics:
Clinical Features:
Pathogenic Variants:
| Variant Type | Examples | Mechanism |
|---|---|---|
| Nonsense mutations | p.Arg528Ter, p.Trp717Ter | Truncated protein, loss of function |
| Frameshift mutations | c.2156_2159del, c.3421delC | Premature termination |
| Splice-site mutations | c.2290-1G>A, c.1595+5G>A | Exon skipping, abnormal splicing |
| Missense mutations | p.Gly551Arg, p.Pro620Leu | Reduced protein function |
The identification of DNAJC6 as a PD gene was significant because it highlighted the importance of synaptic vesicle endocytosis in dopaminergic neuron survival. Unlike other PD genes involved in mitochondrial function (like PARK2 and PINK1), DNAJC6 links neurodegeneration to the endolysosomal pathway[^12].
Homozygous or compound heterozygous DNAJC6 mutations cause a distinct form of juvenile parkinsonism with particularly severe early-onset symptoms. Key features include:
Heterozygous DNAJC6 variants may act as susceptibility factors for atypical parkinsonian disorders. Studies have identified DNAJC6 variants in patients with:
The mechanism appears to involve haploinsufficiency, where reduced protein dosage impairs synaptic vesicle recycling under conditions of cellular stress[^14].
The primary mechanism by which DNAJC6 mutations cause neurodegeneration is through impaired synaptic vesicle endocytosis. Several studies have demonstrated:
Vesicle Pool Depletion: Loss of DNAJC6 function leads to accumulation of clathrin-coated vesicles and depletion of the readily releasable vesicle pool[^15].
Impaired Vesicle Reacidification: DNAJC6 deficiency disrupts the acidification of synaptic vesicles, which is necessary for neurotransmitter loading and vesicle recycling.
Dopamine Transporter (DAT) Defects: Recent research demonstrates that DNAJC6 loss leads to impaired dopamine transporter trafficking and function, contributing to dopaminergic dysfunction[^11].
Synaptic Vesicle Sorting Defects: The endosomal sorting of synaptic vesicles is impaired, leading to abnormal vesicle distribution and reduced quantal content.
A key finding from recent research is that DNAJC6 mutations cause lipid defects that contribute to neurodegeneration:
Phosphoinositide Metabolism: DNAJC6 interacts with SYNJ1 (Synaptojanin 1), a phosphoinositide phosphatase critical for endocytic trafficking. Mutations in both genes cause similar neurodegenerative phenotypes[^16].
Cholesterol Homeostasis: Loss of DNAJC6 disrupts cellular cholesterol distribution, affecting membrane composition and signaling.
Lipid Raft Disruption: The lipid composition of synaptic membranes is altered, affecting receptor signaling and vesicle trafficking.
DNAJC6 deficiency leads to upregulation of pathological alpha-synuclein:
This connection between DNAJC6 dysfunction and alpha-synuclein pathology suggests that endocytic dysfunction may be an early event in the pathogenesis of idiopathic Parkinson's disease.
Given the monogenic nature of DNAJC6-associated parkinsonism, gene therapy represents a promising therapeutic approach:
Several pharmacological strategies are under investigation:
Current clinical management includes:
Several mouse models have been developed to study DNAJC6 function:
Zebrafish provide a complementary model for studying DNAJC6 function during development:
DNAJC6 pathogenic variants are rare in the general population:
| Genotype | Phenotype Severity | Age of Onset |
|---|---|---|
| Two truncating mutations | Severe | <10 years |
| One truncating + one missense | Moderate | 10-20 years |
| Two missense mutations | Mild | 15-25 years |
| Heterozygous | Variable | Adult |